Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist

Song Feng [a,*], Minmin Yang [a], Zhenshan Zhang [a], Zhanguo Wang [a], Di Hong [a], Hans Richter [b],
Gregory Martin Benson [b], Konrad Bleicher [b], Uwe Grether [b], Rainer E. Martin [b],
Jean-Marc Plancher [b], Bernd Kuhn [b], Markus Georg Rudolph [b], Li Chen [a]

[a] Roche R&D Center(China) Ltd, 720 Cai Lun Road, Building 5, Pudong, Shanghai 201203, China
[b] F. Hoffmann-La Roche Ltd, Grenzacherstrasse, CH-4070 Basel, Switzerland

ABSTRACT

According to the docking studies and the analysis of a co-crystal structure of GW4064 with FXR, a series of 3-aryl heterocyclic isoxazole analogs were designed and synthesized. N-Oxide pyridine analog (**7b**) was identified as a promising FXR agonist with potent binding affinity and good efficacy, supporting our hypothesis that through an additional hydrogen bond interaction between the pyridine substituent of isoxazole analogs and Tyr373 and Ser336 of FXR, binding affinity and functional activity could be improved.

© 2009 Elsevier Ltd. All rights reserved.

The Farnesoid X Receptor (FXR), a member of the nuclear receptor superfamily, has bile acids (e.g., chenodeoxycholic acid (CDCA)) as its natural ligands, and plays a key role in regulating cholesterol and bile acid homeostasis.[1–4] The key factor to this function is the ability of bile acid-activated FXR to down-regulate the expression of Cyp7a[1,5,6], which is the rate-limiting step in the liver for the conversion of free cholesterol to bile acids, and the up-regulation of the bile salt excretion pump (BSEP).[7] Treatment of *ob/ob* and *db/db* mice with the synthetic FXR agonist GW4064 (**2**) significantly improves hypercholesterolemia[8] and lowers free fatty acid[9,10] and triglyceride levels in plasma.[11] Similarly, treatment with GW4064 increases insulin sensitivity in *ob/ob* and *db/db* mice.[8,10] As such, FXR agonists may have utility in treating metabolic syndrome, a clustering of cardiovascular risk factors characterized by dyslipidemia (elevated triglyceride and low HDL levels, also add high LDL-c levels), insulin resistance, and poor glucose regulation. Several reviews have summarized the current state of FXR agonists[12,13] and the development of FXR modulators for the treatment of diabetes and metabolic syndrome[14] remains the current focus.

After deorphanization of FXR in 1999[2–4], extensive studies have been directed to the creation of FXR ligands able to modulate FXR-mediated specific gene expression, and several steroidal- and non-steroidal FXR ligands have been described (Fig. 1). Most of the reports deal with FXR agonists (**1**,[11] **2**,[15,16] **3**,[17,18] **4**[19] and **5**[20]), now

compound **5** has recently entered Phase I clinic trials;[21,22] and only few FXR antagonistshave been found so far.[2,3]

GW4064 (**2**) is a well-demonstrated, non-steroid agonist towards FXR, and its biological effects on hyperlipidemia in diabetic mice have been identified and confirmed.[1–4] Since the report of GW4064, a large amount of research work has been directed towards the search replacements of the isoxazole core and the stilbene side-chain.[23–26] Many publications and patents have reported on some new modifications and SAR studies related to GW4064 analogues. So far, most of the modifications around the isoxazole 3-position were limited to modifications of the aryl substituents whereas heterocyclic substituents such as pyridines have been rarely reported.[27]

We report herein the exploration around the 3-aryl substituent of GW4064 and the discovery of an N-oxide pyridine analogue (**7b**), which exhibited highly potent binding affinity and functional activity for FXR, as well as improved physicochemical properties compared with other described GW4064 analogues.

The co-crystal structures of GW4064 and other analogues with FXR have been resolved in-house[28] and reported recently.[29] Analysis of the crystal structure of GW4064 suggested that there are good hydrogen bond interactions between the carbonyl acid group and isoxazole hetero atoms with Arg335, and His451, respectively (Fig. 2). These interactions play important roles for the binding to FXR. In addition to these interactions, some desirable substituents especially on the 3-aryl region of isoxazole could gain more favorable Hydrogen bond interaction with several amino acid residues such as Tyr373/Ser336. Therefore some modifications such as introduction of more polar heterocycles or

Figure 1. Structures of FXR agonists. **1** (6-ECDCA, Intercept), **2** (GW4064, GSK), **3** (Fexaramine, Amgen), **4** (AGN-31, Allergan), and **5** (Exelixis).


Figure 2. Co-crystal structure of GW4064 bound to FXR ligand binding domain (LBD). FXR species: human; resolution: 2.3 Å. Residues in H-bonds are Arg335 and Tyr373, both of which are conserved in FXR (according to PFAM alignment).

substituents toward this position could potentially improve the binding affinity and interaction with the transactivation helix-12. On the other hand, from the point of drug-like properties, the envisaged modifications should help to improve the physico-chemical properties while maintaining a high degree of binding affinity at least.

According to the previous hypothesis, more polar moieties such as methoxy and methylsulfonyl substituents were introduced to the *ortho*- and *para*-positions at the phenyl moiety of isoxazole (Fig. 3, **6b**, **6c**), respectively. Dichloro-pyridine also was utilized to replace the dichloro-phenyl moiety affording compound **6d**. The synthesis of **6b–d** is quite similar to the reported method.[11,30] Dozens of heterocyclic GW4064 analogues with pyridine, N-oxide pyridine, and pyridone as 3-aryl substituent replacements have been designed and synthesized (**7a–h**). Since the phenyl indole side-chain of isoxazole has been revealed recently by Eli Lilly' patent as a good replacement of stilbene[23,25], the phenyl indole carboxylic acid was selected to combine into our design.

The typical synthetic strategy for the preparation of compound (**7b**) is outlined in Scheme 1. The key intermediate **8** was prepared mainly according to the reported synthesis procedure of GW4064 (**6a**) analogues.[11] Pyridine ester **8** was firstly oxidized with *m*-CPBA in refluxing DCE, and then followed by the treatment with trifluoro acetic anhydride to furnish another important intermediate, pyridone ester **9**. The following *o*-methylation of **9** was realized via refluxing with silver carbonate and methyl iodide in chloroform to afford methyl ester **10**. Reduction of the ester moiety in **10** did not work very well in a number of different solvents, however DCM was found to be effective, providing the desired alcohol **11** in 60% yield. Chlorination of alcohol **11** with thionyl chloride in chloroform, followed by oxidation with *m*-CPBA produced N-oxidated pyridine **13**. Deprotonation of phenol **16** with mild base in DMF and subsequent reaction with 4-chloromethyl isoxazole **13** provided coupled intermediate indole aldehyde **14**. Finally, oxidation of the corresponding aldehyde **14** with sodium hypochlorite in *t*-butene/dioxane solution mediated by monobasic sodium phosphate gave rise to the target compound **7b**. Compounds **7a** and **7c–h** were synthesized following similar procedures.

The FXR binding and functional activity data of **6a–d** and **7a–h** are listed in Table 1. Replacement of the 2,6-dichloro substituent with either *ortho*-methoxy (**6b**) or *para*-methylsulfonyl (**6c**) groups resulted in a 3- to 4-fold decrease in binding affinity concomitant with a significant loss in functional activity. Most likely the large methylsulfonyl substituent interferes with the hydrogen bond interaction with FXR, and weakens its activity. 2,6-Dichloro pyridine analogue **6d** showed reduced binding affinity (0.69 μM), however maintained the weak transactivation activity, of which permeability was improved slightly compared with GW4064. Combination of the pyridine head with an optimized stilbene replacement, *N*-methyl indole ring afforded a promising compound **7a**, which exhibited good activity (0.094 μM) in the human SPA binding assay. The predicted membrane permeability was improved, too. Screening of additional analogs led to the discovery of the most potent compound (**7b**) in this series, with a binding affinity of 45 nM. The compound has proved to be a partial agonist (54% and 89% max efficacy relative to GW4064) with an EC$_{50}$ at 0.1 μM, 0.22 μM, **7b** also revealed the best PAMPA data among these series. All other analogues (**7c–h**) exhibited moderate to weak activity either in binding or functional assay, with the exception of **7c** which showed good transactivation activity. The reduced activity might result from the minor changes of the head group orientation, leading to less favorable interactions between the ligands and the binding pocket of FXR.

Figure 3. Designed and synthesized analogues of GW4064.

Scheme 1. The synthesis of N-oxide pyridine and other heterocyclic head GW4064 analogues. Reagents and conditions: (a) DIBAL-H/DCM, rt, 60%; (b) (1) *m*-CPBA/DCE, reflux 3 h; (2) (CF₃CO)₂O/DMF, 8 h, 60%; (c) K₂CO₃/AgI, CHCl₃, 3 h, 80% (d) **10**/K₂CO₃/DMF, 80 °C, 3 h, 70%; (e) Thionyl chloride/CHCl₃, reflux, 2 h, 95%; (f) *m*-CPBA/DCE, reflux, 2 h, 80%; (g) NaClO₂/NaH₂PO₄/*tert*-butene,12 h, 65%; (h) 3-methyl-4-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)phenol, Pd(PPh₃)₄/dioxane/K₃PO₄, 60%.

Table 1
FXR binding and functional activity and predicted permeability for selected GW4064 analogues

Entry	Compounds[32]	IC$_{50}$ SPA[a] (affinity, μM)	EC$_{50}$TA(CH/m-CH[b]) (efficacy, μM)	PAMPA[c] (10^{-6} cm/s)
1	**6a** (GW4064)	0.064	0.9(100%)/2(100%)	0(L)
2	**6b**	0.25	10(54.3%)/10(19.8%)	NA
3	**6c**	0.17	0(>10 μM)/0(>10 μM)	0(L)
4	**6d**	0.69	9(59.4%)/11(48%)	0.09(L)
5	**7a**	0.094	0.9(38%)/3(71%)	0.19(L)
6	**7b**	0.045	0.102(53.7%)/ 0.2(88.5%)	587(H)
7	**7c**	1.10/1.13	5(58.5%)/7(63.3%)	NA
8	**7d**	7.33/1.72	7(12%)/6(17%)	NA
9	**7e**	4.17/2.75	12(9%)/11(15%)	NA
10	**7f**	0.88/0.235	4(27%)/4(39%)	NA
11	**7g**	0.75/0.31	2(23%)/2(12%)	0.7(H)
12	**7h**	5.16/4.13	0(>10 μM)/18(8%)	NA

[a] SPA: scintillation proximity assay, Binding affinity was assessed in a radioligand displacement assay, according to the method reported by Nichols et al.[31]

[b] TA: transactivation activity; (m)-CH: (mouse)-chimeric receptors, TA activity was measured by luciferase transcriptional reporter gene assays,[31] efficacies are relative to GW4064 (set at 100%), the value is a mean.

[c] Kinetic permeability coefficient (Pe). Pe ⩽ 0.2: low (L), Pe > 0.2: medium to high (M&H).

Figure 4. Docked N-oxide pyridine compound (**7b**) in complex with FXR LBD binding site. The helix are shown in ribbon for clarification. Cyan: N-Oxide pyridine analog (**7b**). Left: Helix 12, AF-2 shown in red cartoon; co-activator, SRC-1, shown in yellow; Upper right: superposition of docked **7b** (cyan) and crystallized GW4064 (yellow); Lower right: **7b** complexed with FXR LBD. The potential key hydrogen bonds are indicated by black dash line with the same distance of 2.8 Å.

In conclusion, our exploration on 3-aryl isoxazole moiety of GW4064 has led to the identification of the novel N-oxide pyridine analogue (**7b**) as a potent and efficacious FXR agonist with improved permeability as well. The molecular docking and modelling studies suggest that the oxygen of the N-oxide of isoxazole analogue most likely acts as an H-bond acceptor to interact with Tyr373 on Helix 7 and/or Ser336 on Helix 5 (Fig. 4), leading to

the Helix 5 moving towards Helix 12, the AF-2 activation domain, and then opening up the cleft formed by Helix 3, 4, and 5. Such conformational change results in the release of bound corepressor proteins and the recruitment of co-activator proteins culminating in the transcription of target genes. The N-oxide pyridine analogue (**7b**) revealed here is a novel exploration in search of new GW4064 isoxazole analogues as FXR agonist, and potentially could serve as a promising lead for further optimization.

References and notes

1. Goodwin, B.; Jones, S. A.; Price, R. R.; Watson, M. A.; McKee, D. D.; Moore, L. B.; Galardi, C.; Wilson, J. G.; Lewis, M. C.; Roth, M. E.; Maloney, P. R.; Willson, T. M.; Kliewer, S. A. *Mol. Cell.* **2000**, *6*, 517.
2. Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.; Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.; Shan, B. *Science* **1999**, *274*, 1362.
3. Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B.; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M. *Science* **1999**, *274*, 1365.
4. Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M. *Mol. Cell.* **1999**, *3*, 543.
5. Lu, T. T.; Makishima, M.; Repa, J. J.; Schoonjans, K.; Kerr, T. A.; Auwerx, J.; Mangelsdorf, D. J. *Mol. Cell.* **2000**, *6*, 507.
6. Wang, L.; Lee, Y.-K.; Bundman, D.; Han, Y.; Thevananther, S.; Kim, C.-S.; Chua, S. S.; Wei, P.; Heyman, R. A.; Karin, M.; Moore, D. D. *Dev. Cell.* **2002**, *2*, 721.
7. Ananthanarayanan, M.; Balasubramanian, N.; Makishima, M.; Mangelsdorf, D. J.; Suchy, F. J. *J. Biol. Chem.* **2001**, *276*, 27857.
8. Cariou, B.; Van, H. K.; Duran-Sandoval, D.; Van Dijk, T. H.; Grefhorst, A.; Abdelkarim, M.; Caron, S.; Torpier, G.; Fruchart, J.-C.; Gonzalez, F. J.; Kuipers, F.; Staels, B. *J. Biol. Chem.* **2006**, *271*, 11039.
9. Watanabe, M.; Houten, S. M.; Wang, L.; Moschetta, A.; Mangelsdorf, D. J.; Heyman, R. A.; Moore, D. D.; Auwerx, J. *J. Clin. Invest.* **2004**, *113*, 1408.
10. Zhang, Y.; Lee, F. Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F. J.; Willson, T. M.; Edwards, P. A. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 1006.
11. Maloney, P. R.; Parks, D. J.; Haffner, C. D.; Fivush, A. M.; Chandra, G.; Plunket, K. D.; Creech, K. L.; Moore, L. B.; Wilson, J. G.; Lewis, M. C.; Jones, S. A.; Willson, T. M. *J. Med. Chem.* **2000**, *43*, 2971.
12. . *Trends Biochem. Sci.* **2006**, *31*, 572.
13. Kalaany, N. Y.; Mangelsdorf, D. J. *Annu. Rev. Physiol.* **2006**, *68*, 159.
14. Cariou, B.; Staels, B. *Trends Pharmacol. Sci.* **2007**, *27*, 236.
15. Fujino, T.; Une, M.; Imanaka, T.; Inoue, K.; Nishimaki-Mogami, T. *J. Lipid Res.* **2004**, *45*, 132.
16. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P. R.; Morelli, A.; Parks, D. J.; Willson, T. M. *J. Med. Chem.* **2002**, *45*, 3569.
17. Nicolaou, K. C.; Evans, R. M.; Roecker, A. J.; Hughes, R.; Downes, M.; Pfefferkorn, J. A. *Org. Biomol. Chem.* **2003**, *1*, 908.
18. Dussault, I.; Beard, R.; Lin, M.; Hollister, K.; Chen, J.; Xiao, J. H.; Chandraratna, R.; Forman, B. M. *J. Biol. Chem.* **2003**, *278*, 7027.
19. Love, J. D.; Gooch, J. T.; Benko, S.; Li, C; Nagy, L.; Chatterjee, V. K.; Evans, R. M.; Schwabe, J. W. *J. Biol. Chem.* **2002**, *277*, 11385.
20. Soisson, S. M.; Parthasarathy, G.; Adams, A. D.; Sahoo, S.; Sitlani, A.; Sparrow, C.; Cui, J.; Becker, J. W. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105*, 5337.
21. Mahaney, P.E.; Harnish, D.C.; Abou-Gharbia, M.A.; et al. Abstracts of Papers 235th ACS National Meeting, New Orleans, LA, 2008, Abst MEDI 181.
22. www.clinictrials.gov
23. Bell, M. G.; Genin, M. J.; Lander, P. A.; Stelzer, L. S.; Doti, R. A.; Agejas-Chicharro, F. J.; Bueno Melendo, A. B.; Manninen, P. R.; Ochoada, J. M.; Shen, Q.; Warshawsky, A. M.; Ma, T.; Stites, R. E. Patent WO 2007092751, 2007.
24. Michael G.; Doti, R. A.; Genin, M. J.; Lander, P. A.; Ma, T.; Manninen, P. R.; Ochoada, J. M.; Qu, F.; Stelzer, L. S.; Stites, R. E.; Warshawsky, A. M. Patent WO2007140183, 2007.
25. Bell, M. G.; Doti, R. A.; Dowling, M. S.; Genin, M. J.; Lander, P. A.; Ma, T.; Mantlo, N. B.; Ochoada, J. M.; Stelzer, L. S.; Stites, R. E.; Warshawsky, A. M. Patent WO2007140174, 2007.
26. Kremoser, C.; Deuschle, U.; Abel, U.; Schulz, A. Patent WO2008025539, 2008.
27. Navas F.; Spearing P. K. U.S. Patent 2008096921, 2008.
28. Crystallographic data for the structures in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication numbers CCDC 3FXV.
29. Akwabi-Ameyaw, A.; Bass, J. Y.; Caldwell, R. D.; Caravella, J. A.; Chen, L.; Creech, K. L.; Deaton, D. N.; Jones, S. A.; Kaldor, I.; Liu, Y.; Madauss, K. P.; Marr, H. B.; McFadyen, R. B.; Miller, A. B.; Navas, F., III; Parks, D. J.; Spearing, P. K.; Todd, D.; Williams, S. P.; Wisely, G. B. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4339.
30. Masahiko, K.; Makoto, M.; Yuichi, H.; Hiroyuki, M. *Bioorg. Med. Chem.* **2007**, *15*, 2587.
31. Nichols, J. S.; Parks, D. J.; Consler, T. G.; Blanchard, S. G. *Anal. Biochem.* **1998**, *257*, 112.
32. All new compounds showed satisfactory spectroscopic data.(a) *Selected analytical data*: **6c** MS (ESI⁺), *m/z*: 586.1 (M+H)⁺; Purity: 100% (HPLC); ¹H NMR (400 MHz, DMSO-d_6): 8.18 (d, *J* = 1.2 Hz, 1H), 8.10 (s, 1H), 8.00 (dd, *J* = 2.0, 8.0 Hz), 7.85 (m, 2H), 7.78 (t, *J* = 8.0 Hz, 2H), 7.50 (t, *J* = 7.6 Hz, 1H), 7.40 (d, *J* = 16.4 Hz, 1H), 7.27 (d, *J* = 16.0 Hz, 1H), 6.99 (d, *J* = 2.4 Hz, 1H), 6.81 (dd, *J* = 2.0, 8.8 Hz), 5.00 (s, 2H), 2.50 (t, *J* = 1.6 Hz), 1.35 (d, *J* = 6.8 Hz, 6H).Compound **7b** MS (ESI⁺), *m/z*: 566 (M+H)⁺; Purity: 99.5% (HPLC); ¹H NMR (400 MHz, CDCl₃): 8.35 (s, 2H), 8.22 (d, *J* = 8.0 Hz, 1H), 7.92 (s, 1H), 7.27 (m, 1H), 7.22 (dd, *J* = 8.4, 2H), 6.69 (m, 2H), 4.83 (s, 2H), 3.89 (s, 2H), 3.38 (m, 1H), 2.27 (s, 3H), 1.48 (d, *J* = 7.2 Hz, 6H).Compound **7e** MS (ESI⁺), *m/z*: 580.3 (M+H)⁺; Purity: 99.3% (HPLC); ¹H NMR (400 MHz, CDCl₃): 8.21 (d, *J* = 8.0 Hz, 1H), 7.94 (s, 1H), 7.48 (s, 1H), 7.27 (m, 1H), 7.22 (dd, *J* = 8.4, 2H), 6.75 (m, 2H), 5.81 (br s, 1H), 4.85 (m,1H), 3.89 (s, 3H), 3.67 (s,3H), 3.38 (m, 1H), 2.27 (s, 3H), 1.48 (d, *J* = 7.2 Hz, 6H).Compound **7f** MS (ESI⁺), *m/z*: 546.3 (M+H)⁺; Purity: 99.6% (HPLC); ¹H NMR (400 MHz, CDCl₃): 8.23 (d, *J* = 8.0 Hz), 7.92 (s, 1H), 7.40 (d, *J* = 10.0 Hz), 7.27 (m,1H), 7.22 (m, 2H), 6.71 (m, 3H), 4.95 (d, *J* = 11.6 Hz, 1H), 4.76 (d, *J* = 11.6 Hz, 1H), 3.89 (s, 3H), 3.38 (m, 4H), 2.27 (s, 3H), 1.49 (m, 6H).